Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Go back to Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity| (NASDAQ: RYTM) | Delayed: 103.38 +1.99 (1.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $101.39 | 52 Week High | $ | |||
| Open | $101.00 | 52 Week Low | $ | |||
| Day High | $103.38 | P/E | N/A | |||
| Day Low | $99.49 | EPS | $ | |||
| Volume | 140,627 | |||||
